株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:パイプライン製品の分析

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 271821
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:パイプライン製品の分析 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017
出版日: 2017年11月14日 ページ情報: 英文 48 Pages
概要

メチシリン感受性黄色ブドウ球菌 (MSSA) は、多数の抗生物質に対する耐性を持つ細菌です。MSSAは通常皮膚への感染がみられますが、肺炎やその他重篤な感染症を引き起こす場合があります。蜂巣炎、痛みを伴う発疹、悪心嘔吐、発熱、筋肉の痛み、下痢や腹痛などの症状があり、発病要因は免疫システムの低下、火傷、手術による創傷などです。

当レポートでは、メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Antibiotx ApS
  • ContraFect Corp
  • Debiopharm International SA
  • Sealife PHARMA GMBH

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9890IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 6
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 9
  • Products under Development by Companies 10
  • Products under Development by Universities/Institutes 11
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 12
  • Assessment by Target 12
  • Assessment by Mechanism of Action 14
  • Assessment by Route of Administration 16
  • Assessment by Molecule Type 18
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 20
  • Antibiotx ApS 20
  • ContraFect Corp 20
  • Debiopharm International SA 20
  • Destiny Pharma Ltd 21
  • Sealife PHARMA GMBH 21
  • Tetraphase Pharmaceuticals Inc 22
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles 23
  • afabicin - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • CF-301 - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • exeporfinium chloride - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • NAI-108 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • niclosamide - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • SLP-0904 - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • SLP-0905 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • Small Molecules for Bacterial Infections - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • targocil - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • TP-271 - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46
  • Featured News & Press Releases 46
  • Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 47
  • Disclaimer 48

List of Tables

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Products under Development by Companies, H2 2017 10
  • Products under Development by Universities/Institutes, H2 2017 11
  • Number of Products by Stage and Target, H2 2017 13
  • Number of Products by Stage and Mechanism of Action, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 17
  • Number of Products by Stage and Molecule Type, H2 2017 19
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Antibiotx ApS, H2 2017 20
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corp, H2 2017 20
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H2 2017 21
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Ltd, H2 2017 21
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2017 22
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 22
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2017 44
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2017 45

List of Figures

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Number of Products by Targets, H2 2017 12
  • Number of Products by Stage and Targets, H2 2017 12
  • Number of Products by Mechanism of Actions, H2 2017 14
  • Number of Products by Stage and Mechanism of Actions, H2 2017 14
  • Number of Products by Routes of Administration, H2 2017 16
  • Number of Products by Stage and Routes of Administration, H2 2017 16
  • Number of Products by Molecule Types, H2 2017 18
  • Number of Products by Stage and Molecule Types, H2 2017 18
Back to Top